Section Arrow
GPCR.NASDAQ
- Structure Therapeutics
Quotes are at least 15-min delayed:2025/11/16 13:31 EST
Regular Hours
Last
 36.82
+1.82 (+5.20%)
Day High 
37.5973 
Prev. Close
35 
1-M High
36.49 
Volume 
1.81M 
Bid
36.96
Ask
37.75
Day Low
34.82 
Open
35 
1-M Low
25.5901 
Market Cap 
2.12B 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 33.83 
20-SMA 30.97 
50-SMA 27.55 
52-W High 36.49 
52-W Low 13.22 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-3.66/-3.60
Enterprise Value
2.13B
Balance Sheet
Book Value Per Share
12.69
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
ASBPAspire Biopharma Holdings Inc.0.1063+0.0011+1.05%-- 
CYPHCypherpunk Technologies Inc.2.75+0.99+56.25%-- 
IVVDInvivyd2.35+0.58+32.77%-- 
APLTApplied Therapeutics0.2183-0.0517-19.15%-- 
RXRXRecursion Pharmaceuticals4.14-0.19-4.39%-- 
Quotes are at least 15-min delayed:2025/11/16 13:31 EST
Industry overview quotes are at least 15 minutes delayed
Business Description
Structure Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel oral small-molecule therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its differentiated technology platform leveragesboth structure-based drug discovery and expertise in computational chemistry to discover and develop small molecule therapeutics against G-protein coupled receptors (GPCRs). The group operates and manages its business as one reportable andoperating segment, which is the business of research and development of medicines that target chronic diseases with unmet medical needs.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.